Lundbeck Archives -

News/ News/ R&D

Amid crowded migraine market, Lundbeck goes its own way

Phil Taylor CGRP, Lundbeck, migraine, PACAP, Vyepti 0 Comment

The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting

Amid crowded migraine market, Lundbeck goes its own way

https://pharmaphorum.com/news/amid-crowded-migraine-market-lundbeck-goes-its-own-way/

Digital/ News/ News

Lundbeck taps Inscopix’ brain-mapping camera tech for CNS research

Phil Taylor central nervous system, drug discovery, Inscopix, Lundbeck, neurology, preclinical research 0 Comment

Danish drugmaker Lundbeck has teamed up with Inscopix – the developer of a technology that can film neurons

Lundbeck taps Inscopix’ brain-mapping camera tech for CNS research

https://pharmaphorum.com/news/lundbeck-taps-inscopix-brain-mapping-camera-tech-for-cns-research/

News/ News/ Sales and Marketing

Lundbeck tops Q3 expectations following strong sales of mental health drugs

Richard Staines Lundbeck, mental health, migraine, sales 0 Comment

Denmark’s Lundbeck has beat its expectations in third quarter results, following a strong performance from its portfolio of

Lundbeck tops Q3 expectations following strong sales of mental health drugs

https://pharmaphorum.com/news/lundbeck-tops-q3-expectations-following-strong-sales-of-mental-health-drugs/

News/ News/ R&D

Lundbeck announces plans to cut a fifth of R&D workforce

Richard Staines jobs, Lundbeck, mental health, migraine, neurology, R&D, schizophrenia 0 Comment

Lundbeck has announced plans to cut its research and development team, which could lead to a reduction of

Lundbeck announces plans to cut a fifth of R&D workforce

https://pharmaphorum.com/news/lundbeck-announces-plans-to-cut-around-160-rd-jobs/

Market Access/ News/ News

FDA approves ‘potential blockbuster’ migraine jab from Lundbeck

Richard Staines Allergan, Amgen, Eli Lilly, Lundbeck, migraine, neurology, Novartis, Teva, Vyepti 0 Comment

The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs

FDA approves ‘potential blockbuster’ migraine jab from Lundbeck

https://pharmaphorum.com/news/fda-approves-potential-blockbuster-migraine-jab-from-lundbeck/

Insights/ Sales and Marketing/ White Papers/ Whitepapers

Lundbeck’s digital strategy and how they manage global and local content

louise.bellamy@pharmaphorum.com digital channels, digital strategy, Lundbeck, Veeva 0 Comment

Like all large pharmaceutical companies, Lundbeck operates and manages many different digital marketing and information channels. The Danish

Lundbeck’s digital strategy and how they manage global and local content

https://pharmaphorum.com/sales-marketing/lundbecks-digital-strategy-and-how-they-manage-global-and-local-content/

Digital/ News/ News

Lundbeck joins with Elsevier to help manage R&D data

Richard Staines Elsevier, Lundbeck, R&D 0 Comment

Denmark’s Lundbeck has signed an agreement with information business Elsevier, that aims to help organise the masses of

Lundbeck joins with Elsevier to help manage R&D data

https://pharmaphorum.com/news/lundbeck-joins-with-elsevier-to-help-manage-rd-data/

News/ News/ R&D

Lundbeck craters as resistant schizophrenia drug fails phase III

Phil Taylor Lundbeck, schizophrenia 0 Comment

Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its

Lundbeck craters as resistant schizophrenia drug fails phase III

https://pharmaphorum.com/news/lundbeck-craters-as-resistant-schizophrenia-drug-fails-phase-iii/

News/ News/ R&D/ Top stories

Lundbeck brings third Parkinson’s drug into clinic

Richard Staines Lundbeck, neurology, Parkinson's 0 Comment

Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody

Lundbeck brings third Parkinson’s drug into clinic

https://pharmaphorum.com/news/lundbeck-brings-third-parkinsons-drug-into-clinic/

Trending

Lundbeck

Login